SLDB

6.2702.64%
LM

Lynne Marie Sullivan

Independent Director

Ms. Lynne Marie Sullivan, MST, CPA, was an Independent Director of Tessera Defense and Homeland Security Inc. (formerly known as BiomX Inc.) since November 2019 until March 15, 2024. She served as Independent Director of Inozyme Pharma, Inc. since May 2020 until July 01, 2025. She served as the Chief Financial Officer of Compass Therapeutics LLC since December 19, 2018 to August 2019. Ms. Sullivan served as an Independent Director of resTORbio, Inc. since December 2017. She served as the Chief Financial Officer at Unity Biotechnology, Inc. since September 1, 2020 until June 27, 2025 and served as its Head of Corporate Development since January 29, 2021. She served as an Interim Chief Financial Officer at Unity Biotechnology Inc since August 01, 2020 until September 1, 2020. Ms. Marie is an Independent Director of Solid Biosciences Inc. since November 2015. Ms. Sullivan served as the Senior Vice President of Finance for Biogen Inc. from September 2016 to December 2018, where she has worked since 2008. Ms. Sullivan had global responsibility for Biogen’s Financial Planning & Analysis, Corporate Tax and Corporate Finance groups, which includes ownership of long-range planning, capital allocation projects and the financial aspects of Mergers & Acquisitions/Business Development. Ms. Sullivan was the Vice President of Tax for Biogen from April 2008 to June 2015 and served as its Senior Vice President of Tax and Corporate Finance from February 2015 to March 2016. She served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. She has experience working in the pharma and biotech industry. She was also a Tax Partner at Arthur Andersen, where she led the North East Region’s Tax Consulting Practice for the firm. Ms. Sullivan holds a B.S.B.A. in Accounting from Suffolk University and an M.S. in Taxation from Bentley University. Ms. Sullivan was a certified public accountant.

Positions